Medicine

Evan Ehrenberg PhD '16 co-founded Waterlily, a company that “uses artificial intelligence to predict a family’s future long-term care needs and costs” with the right care and financial planning, reports Mary Ann Azevedo for TechCrunch. “Ehrenberg — who had previously founded and sold Clara Health — helped with early research and was struck by the industry’s response,” writes Azevedo. “Curious, he tested the platform and was shocked by his long-term care predictions — so much so that he changed his diet, hired a personal trainer, and updated his financial plans.” 

In an article for The New York Times, Prof. Pranav Rajpurkar of Harvard and Prof. Eric J. Topol of Scripps highlight a recent study by MIT researchers that examined “how radiologists diagnose potential diseases from chest X-rays.” They write that the study’s findings “broadly indicate that right now, simply giving physicians A.I. tools and expecting automatic improvements doesn’t work. Physicians aren’t completely comfortable with A.I. and still doubt its utility, even if it could demonstrably improve patient care.”

Prof. Giovanni Traverso speaks with the Nature Podcast hosts Benjamin Thompson and Emily Bates about his work developing an ingestible capsule capable of delivering drugs directly into lining of the GI tract. “Part of the work that we did was really defining how much force needs to be applied so that that jet can go through the tissue,” says Traverso. “But not only go through the initial part of the tissue, what we wanted to understand for each part of the GI tract was exactly how much pressure is required to essentially deposit some amount of drug under the surface of the tissue.” 

Prof. Giovanni Traverso speaks with GBH’s “All Things Considered” host Arun Rath about his work developing new approaches to weight loss treatments that don’t involve surgery or pharmaceuticals. “Our team does a lot of work on ingestible systems, ingestible capsules that can do many things,” says Traverso. “You know, we recognize that we live now in a world where we have really incredible therapies that are very effective for the treatment of diabetes and obesity. But we also recognize that they’re not for everybody. There are people who have side effects, people who can’t take them, so these are certainly alternatives, or potentially synergistic interventions, that could work together either with those drugs or, as I was mentioning, for folks that have side effects from the drugs.”

Researchers at MIT have developed a new type of dynamic gastric balloon that inflates on demand and could be used to help patients feel more full before meals, reports Margherita Bassi for Gizmodo. The engineers have “designed a potential future alternative for patients who, for any number of reasons, cannot treat obesity through medications or invasive surgeries such as gastric bypass surgery or stapling,” writes Bassi. 

Boston Business Journal reporter Hannah Green spotlights the MIT Health and Life Sciences Collaborative, a new effort designed to connect researchers, medical professionals, and industry leaders in a shared mission to address some of the most pressing health challenges of our time. Green notes that the collaborative aims to “spur high-impact discoveries and health solutions through interdisciplinary projects across engineering, science, AI, economics, business, policy, design, and the humanities.” 

Professor Giovanni Traverso and his colleagues have developed a new gastric balloon that can be inflated and deflated to mimic feeling full. Unlike traditional gastric balloons, which are one size, the new version is “connected to an external control device that can be attached to the skin and contains a pump that inflates and deflates the balloon when needed,” writes Ernie Mundell for HealthDay. 

MIT researchers have developed a gastric balloon that can inflate before eating and contract afterwards in an effort to ensure the body does not grow accustomed to the balloon, reports Nicola Davis for The Guardian. “What we try to do here is, in essence, simulate the mechanical effects of having a meal,” explains Prof. Giovanni Traverso. “What we want to avoid is getting used to that balloon." 

Using cephalopods, like squid, as inspiration, researchers from MIT, Brigham and Women’s Hospital and Novo Nordisk have developed a capsule that can deliver drugs directly into the digestive track without using needles, writes Corinna Singleman for Genetic Engineering & Biotechnology News. “The capsule design is highly adaptable and was intentionally developed to handle a wide range of drug types,” said Prof. Giovanni Traverso. 

The Economist covers new work by Prof. Giovanni Traverso and his colleagues at Brigham and Women’s Hospital and Novo Nordisk, who have developed an ingestible capsule that can “get medication into patients without having to jab them at all, by copying the jet-propulsion techniques used by squid and their kin.” 

Prof. Giovanni Traverso and his colleagues have developed a new device, inspired by sea creatures, that can deliver drugs orally by using jets to “eject drugs into the tissue lining the digestive tract," reports Anil Oza for STAT. “We want to make it easier for patients to receive medication,” says Traverso. “The challenge with drugs like insulin and monoclonal antibodies is that they require an injection. That in and of itself can be a barrier for receiving that medication.” 

Researchers at MIT have developed a new AI model capable of assessing a patient’s risk of pancreatic cancer, reports Erez Meltzer for Forbes. “The model could potentially expand the group of patients who can benefit from early pancreatic cancer screening from 10% to 35%,” explains Meltzer. “These kinds of predictive capabilities open new avenues for preventive care.” 

MIT researchers have developed a biosensor “the size of a stick of gum that can be implanted under the skin and deliver naloxone if vital signs indicate an overdose,” reports David Ovalle and Elana Gordon for The Washington Post. 

The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros '75, PhD '79 and Gary Ruvkun for the discovery of microRNA, “a tiny class of RNA molecules that play a crucial role in determining how organisms mature and function – and how they sometimes malfunction,” reports Teddy Rosenbluth and Derrick Bryson Taylor for The New York Times. Ambros and Ruvkun “had been postdoctoral fellows at the same time at Massachusetts Institute of Technology,” they explain . “As they studied C. elegans, they at first felt a smidgen of friendly competition as they each started their own labs in the Boston area, Dr. Ambros said.”

Victor Ambros '75, PhD '79 and Gary Ruvkun have won the 2024 Nobel Prize in Physiology or Medicine for the discovery of microRNAs, report Mark Johnson and Lizette Ortega for The Washington Post. “Ambros and Ruvkunhad worked together as postdoctoral researchers in the lab of Nobel laureate and MIT Professor Robert Horvitz. “What the microRNAs really end up revealing for us is a way that parts of our genome can communicate with other parts of the genome,” says Ambros. “The significance of this discovery of microRNAs is that it allowed us to be aware of a very complex and nuanced layer of regulation whereby genes in our cells talk to each other.”